Lefamulin

Lefamulin
Clinical data
Trade names	Xenleta
Other names	BC-3781
AHFS/Drugs.com	Monograph
License data	US DailyMed: Lefamulin;
Routes of; administration	Intravenous, by mouth
ATC code	J01XX12 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name (1S,2R,3S,4S,6R,7R,8R,14R)-3-Hydroxy-2,4,7,14-tetramethyl-9-oxo-4-vinyltricyclo[5.4.3.01,8]tetradec-6-yl {[(1R,2R,4R)-4-amino-2-hydroxycyclohexyl]sulfanyl}acetate;
CAS Number	1061337-51-6;
PubChem CID	25185057;
DrugBank	DB12825;
ChemSpider	32701544;
UNII	21904A5386;
KEGG	D11631;
ChEMBL	ChEMBL3291398;
CompTox Dashboard (EPA)	DTXSID101027896 ;
Chemical and physical data
Formula	C28H45NO5S
Molar mass	507.73 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@@]1([C@@H](C[C@@]([C@H]([C@@H]3C)O)(C)C=C)OC(=O)CS[C@@H]4CC[C@H](C[C@H]4O)N)C;
	InChI InChI=1S/C28H45NO5S/c1-6-26(4)14-22(34-23(32)15-35-21-8-7-18(29)13-20(21)31)27(5)16(2)9-11-28(17(3)25(26)33)12-10-19(30)24(27)28/h6,16-18,20-22,24-25,31,33H,1,7-15,29H2,2-5H3/t16-,17+,18-,20-,21-,22-,24+,25+,26-,27+,28+/m1/s1; Key:KPVIXBKIJXZQJX-FCEONZPQSA-N;

Lefamulin, sold under the brand name Xenleta, is an antibiotic medication used it to treat adults with community-acquired bacterial pneumonia. It is taken by mouth or by injection into a vein.

Relatively common side effects include diarrhea, nausea, pain at the site of injection, and liver inflammation. It is a pleuromutilin antibiotic that inhibits the large subunit of bacterial ribosomes.

Lefamulin was approved for medical use in the United States in August 2019, and in the European Union in July 2020.